These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.